Gilteritinib
Gilteritinib is a potent and selective inhibitor of FLT3 (FMS-like tyrosine kinase 3) and AXL receptor tyrosine kinases. It is classified as a targeted therapy medication used in the treatment of certain types of blood cancers, specifically acute myeloid leukemia (AML) characterized by FLT3 mutations.Treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation, as detected by an FDA-approved test.
-The recommended dosage of gilteritinib is typically 120 mg orally once daily. -Administer with or without food, and swallow the tablets whole.
Hypersensitivity to gilteritinib or any component of the formulation.
-Monitor for signs of differentiation syndrome, which may include fever, respiratory distress, and multiorgan dysfunction. Manage promptly with corticosteroids and supportive care. -Assess cardiac function, including electrocardiograms (ECGs), due to potential QT interval prolongation. -Use with caution in patients with hepatic impairment; adjust dosage if necessary based on liver function tests.
Common side effects of gilteritinib may include: -Fatigue -Elevated liver enzymes -Myalgia (muscle pain) -Dizziness -Edema (swelling)
Gilteritinib may interact with medications that prolong the QT interval or are metabolized by CYP3A4 enzymes. Avoid concomitant use with strong CYP3A4 inhibitors or inducers.
